Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 60 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Neuro+ Clear all
Not listed No phase listed Observational

A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients

NCT01594541
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Pamlab, Inc.
Industry
Eligibility
55 Years to 89 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 3, 2026, 2:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

NCT05363293
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
Interventions
AL001, Placebo
Drug · Other
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 3, 2026, 2:57 PM EDT
Active, not recruiting Phase 1 Interventional

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

NCT04323046
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III Glioma
Interventions
Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
6 Months to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 3, 2026, 2:57 PM EDT
Completed No phase listed Observational

Development of an EEG Diagnostic for Alzheimer's Disease

NCT04954183
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Dementia With Lewy Bodies, Normal Control APOE e4 Carriers and Noncarriers
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 3, 2026, 2:57 PM EDT
Recruiting Not applicable Interventional

Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma

NCT07506239
View directory record Official record
Conditions
Low-grade Glioma, Recurrent Low Grade Glioma, Low Grade Glioma of Brain, Pediatric Cancer
Interventions
Laser Interstitial Thermal Therapy (LITT), Magnetic resonance imaging (MRI), Questionnaires
Device · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 3, 2026, 2:57 PM EDT
Completed Phase 1 Interventional

DAY101 In Gliomas and Other Tumors

NCT03429803
View directory record Official record
Conditions
Low-grade Glioma
Interventions
DAY101
Drug
Lead sponsor
Karen D. Wright, MD
Other
Eligibility
1 Year to 25 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 3, 2026, 2:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

NCT02960230
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
K27M peptide, Nivolumab
Biological · Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
3 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
14
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 3, 2026, 2:57 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

NCT04775485
View directory record Official record
Conditions
Low-grade Glioma, Advanced Solid Tumor
Interventions
Tovorafenib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
6 Months to 25 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 3, 2026, 2:57 PM EDT
Completed No phase listed Observational

A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning - Nelli

NCT05606575
View directory record Official record
Conditions
Epilepsy
Interventions
Nelli
Device
Lead sponsor
Neuro Event Labs Inc.
Industry
Eligibility
6 Years to 21 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 3, 2026, 2:57 PM EDT
Recruiting Phase 1 Interventional

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

NCT04573140
View directory record Official record
Conditions
Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
Interventions
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Biological
Lead sponsor
University of Florida
Other
Eligibility
4 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 3, 2026, 2:57 PM EDT
Completed Not applicable Interventional

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

NCT03739372
View directory record Official record
Conditions
Glioma, Glioma of Brain, Cancer, Pediatric Cancer, Pediatric Brain Tumor, Astrocytoma, Glioblastoma, Hemispheric
Interventions
Specialized tumor board recommendation
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 3, 2026, 2:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Assessment of Gesture Accuracy of a Prosthesis Control System

NCT06446037
View directory record Official record
Conditions
Upper Limb Amputation Below Elbow (Injury)
Interventions
Non-invasive EMG band instrumentation
Device
Lead sponsor
Phantom Neuro Inc.
Industry
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 3, 2026, 2:57 PM EDT
Recruiting Not applicable Interventional

Brain Stimulation Paired With Structured Reading Instruction in Children With Dyslexia

NCT07762365
View directory record Official record
Conditions
Dyslexia, Reading Disability
Interventions
Active transcranial electrical stimulation (tES), Sham transcranial electrical stimulation (tES)
Device
Lead sponsor
General Neuro Inc.
Industry
Eligibility
7 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 3, 2026, 2:57 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery

NCT03579602
View directory record Official record
Conditions
Pediatric Central Nervous System Tumor
Interventions
tozuleristide, Canvas System
Drug · Device
Lead sponsor
Blaze Bioscience Inc.
Industry
Eligibility
1 Month to 30 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 3, 2026, 2:57 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional Accepts healthy volunteers

Aerobic Exercise After Traumatic Brain Injury

NCT05786729
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Aerobic Exercise (AER), Rehabilitation
Other
Lead sponsor
Centre for Neuro Skills
Industry
Eligibility
18 Years to 60 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bakersfield, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 3, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Traumatic Brain Injury and the Gut Microbiome

NCT04949607
View directory record Official record
Conditions
Brain Injury, Chronic, Brain Injuries, Traumatic
Interventions
Inulin fructooligosaccharide
Dietary Supplement
Lead sponsor
Centre for Neuro Skills
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bakersfield, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 3, 2026, 2:57 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The DIAGNOSE CTE Research Project-II

NCT06860828
View directory record Official record
Conditions
Chronic Traumatic Encephalopathy (CTE), Alzheimer Disease, Alzheimer Disease and Related Dementias (ADRD), Brain Injuries, Traumatic
Interventions
Not listed
Lead sponsor
Boston University
Other
Eligibility
50 Years and older · Male only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
5
States / cities
Phoenix, Arizona • San Francisco, California • Gainesville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 3, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The REMIND Study- SPARK Neuro Software Study

NCT05406778
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Impairment
Interventions
SPARK Test
Device
Lead sponsor
Spark Neuro Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
7
States / cities
Loma Linda, California • Englewood, Colorado • Ocala, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 3, 2026, 2:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis

NCT01987167
View directory record Official record
Conditions
Optic Neuritis
Interventions
ACTHAR
Drug
Lead sponsor
Neuro-Ophthalmologic Associates, PC
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 3, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy

NCT00090376
View directory record Official record
Conditions
Impotence, Prostate Cancer
Interventions
GPI 1485
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
40 Years to 69 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
25
States / cities
Phoenix, Arizona • La Mesa, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2008 · Synced Oct 3, 2026, 2:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

NCT03690869
View directory record Official record
Conditions
Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
Interventions
cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation
Drug · Radiation
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Up to 25 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 3, 2026, 2:57 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

NCT05834296
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo
Biological · Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 3, 2026, 2:57 PM EDT
Completed No phase listed Observational

A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning

NCT04738552
View directory record Official record
Conditions
Epilepsy
Interventions
Nelli
Device
Lead sponsor
Neuro Event Labs Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 3, 2026, 2:57 PM EDT
Completed Phase 1 Interventional

CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)

NCT03086616
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
2 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 3, 2026, 2:57 PM EDT